Display options
Cite
Dehpouri T, Rokni GR, Narenjbon NA, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Reports. 2019;11(1):7965doi: 10.4081/dr.2019.7965.
Dehpouri, T., Rokni, G. R., Narenjbon, N. A., Goldust, M., Yamauchi, P. S., Wollina, U., Lotti, T., Kircik, L., Lernia, V. G. D., Sonthalia, S., Vojvodic, A., Szepietowski, J., Bahadoran, P., Errichetti, E., Cantisani, C., Atzori, L., Rezaee, E., Kutlubay, Z., Engin, B., Nisticò, S., Damiani, G., Conic, R. R. Z., Goren, A., Čabrijan, L., & Tchernev, G. (2019). Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology reports, 11(1), 7965. https://doi.org/10.4081/dr.2019.7965
Dehpouri, Tannaz, et al. "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study." Dermatology reports vol. 11,1 (2019): 7965. doi: https://doi.org/10.4081/dr.2019.7965
Dehpouri T, Rokni GR, Narenjbon NA, Goldust M, Yamauchi PS, Wollina U, Lotti T, Kircik L, Lernia VGD, Sonthalia S, Vojvodic A, Szepietowski J, Bahadoran P, Errichetti E, Cantisani C, Atzori L, Rezaee E, Kutlubay Z, Engin B, Nisticò S, Damiani G, Conic RRZ, Goren A, Čabrijan L, Tchernev G. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Reports. 2019 May 09;11(1):7965. doi: 10.4081/dr.2019.7965. eCollection 2019 Jan 23. PMID: 31210916; PMCID: PMC6547029.
Copy Download .nbib Format: NLM
Share it on

Dermatol Reports. 2019 May 09;11(1):7965. doi: 10.4081/dr.2019.7965. eCollection 2019 Jan 23.

Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study.

Dermatology reports

Tannaz Dehpouri, Ghasem Rahmatpour Rokni, Nematollah Ahangar Narenjbon, Mohamad Goldust, Paul S Yamauchi, Uwe Wollina, Torello Lotti, Leon Kircik, Vito Giuseppe Di Lernia, Sidharth Sonthalia, Aleksandra Vojvodic, Jacek Szepietowski, Philippe Bahadoran, Enzo Errichetti, Carmen Cantisani, Laura Atzori, Elham Rezaee, Zekayi Kutlubay, Burhan Engin, Steven Nisticò, Giovanni Damiani, Rosalynn R Z Conic, Andy Goren, Leo Čabrijan, Georgi Tchernev

Affiliations

  1. Student Research Committee, Mazandaran University of Medical Sciences, Ramsar International Branch, Ramsar, Iran.
  2. Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran.
  3. Department of Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
  4. Dermatology Institute and Skin Care Center, Santa Monica, California, USA.
  5. Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
  6. Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
  7. Department of Dermatology, "Guglielmo Marconi" University, Rome, Italy.
  8. Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  9. Dermatology Unit, Santa Maria Nuova-IRCCS Hospital, Reggio Emilia, Italy.
  10. Skinnocence: The Skin Clinic & Research Center, Gurugram, Haryana, India.
  11. Dermasource India, Gurugram, Haryana, India.
  12. Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia.
  13. Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  14. Department of Dermatology, University Hospital of Nice, Nice, France.
  15. Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy.
  16. Department of Dermatology, "Umberto I" Hospital, "Sapienza" University of Rome, Rome, Italy.
  17. Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  18. Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  19. Department of Dermatology, Cerrahpasa Faculty of Medicine, University of Istanbul, Istanbul, Turkey.
  20. Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  21. Department of Medical and Surgical Pathophysiology and Transplantation, University of Milan, Dermatology Unit, IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
  22. Young Dermatologists Italian Network (YDIN), Centro Studi GISED, Bergamo, Italy.
  23. Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
  24. Department of Dermatovenereology, Rijeka Clinical Hospital Center, Rijeka, Croatia.
  25. Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.

PMID: 31210916 PMCID: PMC6547029 DOI: 10.4081/dr.2019.7965

Abstract

Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.

Keywords: HbA1c; Metabolic syndrome; Methotrexate; Psoriatic arthritis

Conflict of interest statement

Conflict of interest: the authors declare no potential conflict of interest.

References

  1. BMJ. 2001 Jan 6;322(7277):15-8 - PubMed
  2. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  3. Lancet. 2002 Apr 6;359(9313):1173-7 - PubMed
  4. Arthritis Res. 2002;4(6):R12 - PubMed
  5. J Clin Endocrinol Metab. 2003 Aug;88(8):3773-6 - PubMed
  6. Cytokine Growth Factor Rev. 2003 Oct;14(5):447-55 - PubMed
  7. Soc Sci Med. 2005 Apr;60(7):1571-82 - PubMed
  8. J Am Acad Dermatol. 2005 Feb;52(2):262-7 - PubMed
  9. Arthritis Rheum. 2005 Feb;52(2):412-20 - PubMed
  10. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  11. Arthritis Rheum. 2006 Aug;54(8):2665-73 - PubMed
  12. Arch Dermatol Res. 2006 Dec;298(7):321-8 - PubMed
  13. Diabet Med. 2006 Nov;23(11):1270-1 - PubMed
  14. Mayo Clin Proc. 2006 Dec;81(12):1615-20 - PubMed
  15. Acta Derm Venereol. 2007;87(6):506-9 - PubMed
  16. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4 - PubMed
  17. Pharmacol Res. 2008 Apr;57(4):290-5 - PubMed
  18. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19396-401 - PubMed
  19. Autoimmun Rev. 2009 Mar;8(5):415-9 - PubMed
  20. Dermatol Ther. 2009 Jan-Feb;22(1):61-73 - PubMed
  21. Clin Rheumatol. 2009 Oct;28(10):1217-20 - PubMed
  22. Am J Clin Pathol. 2009 Aug;132(2):161-2 - PubMed
  23. J Rheumatol Suppl. 2009 Aug;83:4-8 - PubMed
  24. J Intern Med. 2011 Aug;270(2):147-57 - PubMed
  25. Arch Dermatol. 2011 Apr;147(4):419-24 - PubMed
  26. JAMA. 2011 Jun 22;305(24):2525-31 - PubMed
  27. Prev Med. 2012 May;54(5):363-4; author reply 365 - PubMed
  28. Ann Rheum Dis. 2012 Apr;71(4):480-3 - PubMed
  29. J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:3-11 - PubMed
  30. J Intern Med. 2013 Feb;273(2):197-204 - PubMed
  31. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1262-8 - PubMed
  32. J Am Acad Dermatol. 2013 Apr;68(4):654-662 - PubMed
  33. J Dermatolog Treat. 2015 Feb;26(1):7-15 - PubMed
  34. Arthritis Rheumatol. 2014 Aug;66(8):2026-36 - PubMed
  35. J Drugs Dermatol. 2015 Feb;14(2):159-66 - PubMed
  36. Scand J Rheumatol. 2016 Oct;45(5):347-55 - PubMed
  37. Circ Cardiovasc Imaging. 2017 Jul;10(7):null - PubMed
  38. J Rheumatol. 1994 Dec;21(12):2286-91 - PubMed
  39. Arthritis Rheum. 1995 Jan;38(1):44-8 - PubMed

Publication Types